Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briakinumab vs Etanercept in Moderate to Severe Plaque Psoriasis
NCT00710580Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2008
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of briakinumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Jul 2008; status: completed.
02
Drugs
briakinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00710580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00710580.